The GLP-1 Titration Schedule: Why Slow, and What to Expect at Each Dose Step

What titration is and why GLP-1s require it

Titration is the practice of starting a drug at a low dose and gradually increasing to the target therapeutic dose over a defined schedule. Many drugs do not require titration — you take the prescribed dose from day one. GLP-1 drugs are different, and the reason is their side-effect profile.

The GI effects of GLP-1 agonists — nausea, vomiting, constipation, occasional diarrhea — are most intense in the first one to two weeks after starting the drug or after a dose increase. They are largely driven by the drug's effect on gastric emptying: GLP-1 slows the stomach, which produces fullness signals at lower food volumes and, in some patients, frank GI distress. The body adapts to each level within a few weeks — gastric emptying normalizes somewhat at each new equilibrium — before tolerating the next step up.

Starting at full therapeutic dose would produce severe, often intolerable side effects in most patients. The titration schedule exists to spread out the GI adaptation over months, keeping each step manageable.

The semaglutide (Wegovy) schedule

For Wegovy (semaglutide for chronic weight management), the FDA-approved schedule is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 and beyond: 2.4 mg once weekly (maintenance)

Total titration period: roughly 16-17 weeks. Maintenance dose: 2.4 mg weekly. For Ozempic (semaglutide for type 2 diabetes), the schedule and target dose are different — typically 0.25 mg, 0.5 mg, then 1.0 mg, with 1.0 mg as a common maintenance dose (and 2.0 mg available for additional glycemic control).

The 4-week interval at each dose is the minimum interval; longer intervals are acceptable if a patient is tolerating the current dose poorly. Going faster than 4 weeks per step is not recommended and substantially increases the risk of intolerable side effects.

The tirzepatide (Zepbound) schedule

For Zepbound (tirzepatide for chronic weight management):

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly
• Week 21 and beyond: 15 mg once weekly (maintenance)

Total titration: roughly 20 weeks to maximum dose. For Mounjaro (tirzepatide for diabetes), titration is similar, and maintenance doses vary based on glycemic targets. Many patients stop titrating at 10 mg or 12.5 mg if they are tolerating well and achieving adequate weight loss — the maximum dose is not always necessary or optimal.

What happens at each dose step (biologically)

The biology behind why titration works follows a consistent pattern at each step:

Days 1-3 after a dose increase: peak GI effects. Nausea is most intense; appetite suppression most noticeable; gastric emptying most slowed. Some patients experience vomiting or marked discomfort. This is the trough of tolerability.

Days 4-10: partial adaptation. The body begins normalizing some of the gastric motility effects; nausea subsides somewhat; appetite signaling stabilizes at a new lower set point. Patients who get past day 7-10 usually find the new dose tolerable.

Days 11-28: equilibrium at the new dose. Side effects are minimal between meals; food intake is reduced but comfortable; the drug is producing its therapeutic effect. By the end of week 4, the body is ready (or not) for the next step up.

This cycle repeats at each titration step. The patients who tolerate titration well are typically the ones who get past the first 7-10 days of each dose increase.

When to pause or slow down

The official schedule is a maximum-speed protocol — not a mandatory one. Many patients benefit from slower titration:

• Persistent severe nausea beyond 10-14 days at a new dose suggests the body has not adapted. Staying at the current dose for an additional 4 weeks before stepping up is often more effective than pushing forward.
• Vomiting at any frequency warrants pausing before the next dose increase — and discussing with a prescriber whether to reduce or pause.
• Significant weight loss already at a lower dose may not require continued escalation. Many patients reach their goals at 1.0-1.7 mg semaglutide or 7.5-10 mg tirzepatide rather than the maximum dose.
• Other life stress, illness, or travel coinciding with a planned dose increase is a reasonable reason to delay the step up by a few weeks.

Pausing at a tolerated dose for an extra 4 weeks does not cost anything in long-term outcomes. Rushing forward and dropping out costs everything.

Why faster doesn't mean better

The temptation to titrate faster than the official schedule comes from a few directions: impatience for results, the assumption that a higher dose is always better, and clinical pressure to hit a goal weight by a deadline. None of these survive contact with the data.

Real-world studies show that the strongest predictor of long-term weight loss on GLP-1 therapy is staying on the drug — not the dose reached. Patients who titrate aggressively, develop intolerable side effects, and discontinue lose less weight than patients who titrate slowly, tolerate well, and stay on a lower maintenance dose for years.

The other reason: the dose-response curve flattens at higher doses for most patients. The difference in weight loss between 1.7 mg and 2.4 mg semaglutide is modest; between 10 mg and 15 mg tirzepatide is modest. Many patients can achieve 90-95% of their potential weight loss at a sub-maximum dose, with substantially better tolerability.

The honest read

The titration schedule is not bureaucratic over-caution — it is the bridge between the drug working and the patient being able to keep taking it. Most discontinuation happens during titration, and most of that discontinuation is preventable through slower pacing, longer holds at intermediate doses, and willingness to skip the maximum dose if results are already adequate. The honest version of the advice: respect the official schedule as a maximum speed, not a target speed, and remember that any week spent at a tolerated dose is a week of continued therapy.